Hermetica Superfood Encyclopedia
The Short Answer
Icariside II is a bioactive flavonoid glycoside derived from Epimedium species (horny goat weed) and a primary metabolite of icariin following intestinal hydrolysis. It exerts its effects primarily through modulation of VEGF signaling, MMP2 inhibition, and apoptotic pathway activation, making it a subject of active preclinical oncology and anti-inflammatory research.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary KeywordIcariside II benefits
Synergy Pairings3
Icariside II — botanical close-up
Health Benefits
Origin & History
Natural habitat
Icariside II is a prenylated flavonoid glycoside naturally occurring in Epimedium species (horny goat weed), appearing as yellow needle-shaped crystals. It is produced as the main metabolite of icariin through enzymatic hydrolysis in the body, with a molecular formula of C27H30O10.
“While Icariside II itself has no documented traditional use, it derives from Herba Epimedii (Epimedium species), which has been used in Traditional Chinese Medicine. Specific historical applications for the isolated compound are not detailed in available sources.”Traditional Medicine
Scientific Research
No human clinical trials, RCTs, or meta-analyses for Icariside II have been conducted. All available evidence is limited to preclinical cell culture and animal studies demonstrating anticancer effects through various molecular pathways.
Preparation & Dosage
Traditional preparation
No clinically studied dosage ranges are available due to absence of human trials. Preclinical formulations include phospholipid complexes and TPGS combinations, but human doses have not been established. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Icariside II is a flavonoid glycoside (specifically a prenylflavonoid) derived from Epimedium species (Horny Goat Weed), functioning as a bioactive compound rather than a nutritional macronutrient — it contains no meaningful protein, fat, fiber, or caloric value in supplemental context. It is a metabolite of Icariin, formed via enzymatic hydrolysis removing one sugar moiety, yielding higher bioavailability than its parent compound Icariin. Molecular weight: approximately 676.7 g/mol. Typical concentrations in standardized Epimedium extracts range from 0.1–2% by weight, with isolated supplemental forms appearing in research doses of 10–100 mg in preclinical studies. Bioavailability is notably superior to Icariin due to reduced glycosylation; oral absorption is facilitated by intestinal glycosidases, though precise human bioavailability percentages remain unestablished. It demonstrates lipophilic characteristics that may enhance membrane permeability. No significant vitamin, mineral, or fiber content is associated with the isolated compound.
How It Works
Mechanism of Action
Icariside II suppresses tumor angiogenesis by downregulating vascular endothelial growth factor (VEGF) expression and inhibiting matrix metalloproteinase-2 (MMP2) activity, which reduces cancer cell migration and invasion. It promotes apoptosis by activating caspase-3 and caspase-9 cascades while modulating the Bcl-2/Bax ratio in favor of pro-apoptotic signaling. Additionally, it inhibits NF-κB pathway activation, reducing downstream production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in preclinical inflammatory models.
Clinical Evidence
Research on Icariside II remains almost entirely at the in vitro and rodent model stage, with no completed randomized controlled trials in humans as of 2024. Cell-based studies have demonstrated dose-dependent inhibition of proliferation in prostate, breast, and hepatocellular carcinoma cell lines at concentrations ranging from 10 to 80 μM. Animal studies in murine models of inflammation showed statistically significant reductions in paw edema and inflammatory biomarkers, though translational relevance to human dosing is unestablished. The overall evidence base is preliminary, and no clinical efficacy or safety conclusions can be drawn for human supplementation.
Safety & Interactions
Human safety data for isolated Icariside II supplementation is essentially absent, as most toxicology data comes from its parent compound icariin and whole Epimedium extracts. Epimedium-based products have been associated with hepatotoxicity in case reports and may potentiate anticoagulant medications such as warfarin by inhibiting CYP450 enzymes including CYP3A4. Icariside II should be avoided during pregnancy and breastfeeding due to a complete lack of safety data and theoretical hormonal activity given its phytoestrogenic structural properties. Individuals on antihypertensive or hormone-sensitive medications should consult a physician before use.
Synergy Stack
Hermetica Formulation Heuristic
Frequently Asked Questions
What is Icariside II and how is it different from icariin?
Icariside II is a direct metabolite of icariin, the primary flavonoid glycoside in Epimedium (horny goat weed), produced when intestinal enzymes cleave one sugar moiety from icariin's structure. This structural difference increases Icariside II's bioavailability and cellular uptake compared to icariin, making it more pharmacologically active per unit dose in preclinical assays. Some researchers consider Icariside II the true active form responsible for many of the biological effects historically attributed to icariin itself.
Can Icariside II kill cancer cells?
Preclinical cell studies show Icariside II can induce apoptosis in cancer cell lines including prostate (LNCaP), breast (MCF-7), and liver (HepG2) cancers at concentrations of 10–80 μM by activating caspase-3/9 and altering Bcl-2/Bax ratios. However, these are laboratory findings only, and no human clinical trials have evaluated Icariside II as a cancer treatment. It should not be considered a cancer therapy, and anyone with cancer should not substitute it for evidence-based medical treatment.
What foods or plants contain Icariside II naturally?
Icariside II is not abundantly present as a standalone compound in dietary foods but is found in small quantities in plants of the Epimedium genus, including species such as Epimedium brevicornum, Epimedium sagittatum, and Epimedium koreanum. It is also generated endogenously in the gut through microbial and enzymatic conversion of icariin after consumption of Epimedium-containing supplements or herbal preparations. Standardized Epimedium extracts are the most practical dietary source, though the exact Icariside II content varies significantly by species and extraction method.
Is Icariside II safe to take daily as a supplement?
There is currently no established safe daily dosage for isolated Icariside II in humans, as no clinical pharmacokinetic or safety trials have been completed. Tolerability data is extrapolated from icariin and whole Epimedium research, where doses up to 1,000 mg/day of standardized extract have been used short-term without severe adverse events, but isolated Icariside II at therapeutic concentrations remains unstudied. Until human safety data exists, daily supplementation of isolated Icariside II cannot be recommended with confidence, particularly for individuals with liver conditions or those on prescription medications.
Does Icariside II interact with any medications?
Icariside II and its parent compound icariin are suspected inhibitors of CYP3A4 and CYP2C9 liver enzymes, which metabolize a wide range of medications including warfarin, statins, and certain immunosuppressants, potentially raising their blood levels to dangerous concentrations. There is also theoretical interaction with estrogen-based hormone therapies due to Icariside II's phytoestrogenic activity at estrogen receptor beta (ERβ). Patients taking blood thinners, hormone therapies, or medications with narrow therapeutic windows should consult their prescribing physician before using any Epimedium-derived supplement.
How strong is the current scientific evidence for Icariside II's health benefits?
Most evidence for Icariside II comes from laboratory cell studies and animal models rather than human clinical trials, which limits our ability to confirm effectiveness in people. While preliminary research suggests potential anti-inflammatory and anti-cancer properties through mechanisms like VEGF inhibition and apoptosis induction, these findings have not been validated in rigorous human studies. Current evidence is considered preclinical and exploratory, meaning more research is needed before strong health claims can be made. Healthcare providers typically recommend caution when relying on Icariside II for therapeutic purposes until human clinical data becomes available.
Who should avoid Icariside II or use it with caution?
People with hormone-sensitive conditions (such as certain breast cancers or endometriosis) should consult a healthcare provider before using Icariside II, as some epimedium compounds exhibit estrogenic activity. Pregnant and breastfeeding women should avoid Icariside II due to insufficient safety data in these populations. Individuals undergoing cancer treatment or taking immunosuppressant medications should seek medical guidance, given the compound's potential effects on cell growth pathways and immune function in preliminary studies. Those with bleeding disorders or taking anticoagulants may also need to exercise caution, though human safety data is limited.
Does the bioavailability of Icariside II differ from its parent compound icariin, and does this affect supplementation?
Icariside II is a metabolite created when icariin is broken down in the body, meaning it may have different absorption and tissue distribution patterns than icariin itself. Some research suggests that Icariside II may accumulate in specific tissues and have enhanced bioavailability for certain cellular targets compared to the parent compound. However, direct human bioavailability studies comparing the two compounds are scarce, making it difficult to determine which form is more effective for supplementation purposes. Standardization and delivery method of Icariside II products can vary significantly between manufacturers, potentially affecting real-world effectiveness.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w icariside-ii curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
